In oral cancer, the PD-L1 immune checkpoint acts as a tumour biomarker that can help in selecting patients for immunotherapy; monitoring patient response to immunotherapy and in assessing tumour prognosis and is correlated with clinicopathological features [17]. This evidence concerns the gene CD274 and lip and oral cavity carcinoma.